Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Phase I Trial.

Created on 17 Nov 2026

Authors

Juan C Osorio, Lucas Blanchard, Ning Yao, Syed M Alam, Ali Ghasemzadeh, Steven Grudman, Karissa Whiting, Venkatraman E Seshan, Andrew Mijacika, Carlo Sevilla, Juan C Angulo-Lozano, Ved P Sharma, Morgan Tomberlin, Melissa McCarter, Jessica Pfau, Jeffrey L Wong, David A Knorr, Timothy F Donahue, Robert Smith, Eugene J Pietzak, Benjamin Greenbaum, Hikmat Al-Ahmadie, Jonathan E Rosenberg, Jeffrey V Ravetch, Bernard Bochner

Published in

Clinical cancer research : an official journal of the American Association for Cancer Research. Nov 17, 2026. Epub Nov 17, 2026.

Abstract

CD40 agonists activate dendritic cells (DCs) and promote T-cell antitumor immunity, but clinical development has been limited by systemic toxicity and incomplete understanding of determinants of response. In this phase I study (NCT05126472), we evaluated the safety, preliminary clinical activity, and spatial immune correlates of response to intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Patients received weekly intravesical instillations for 3 weeks, with retreatment at weeks 13 and 25 based on disease status. Primary objectives were safety, tolerability, and determination of the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Secondary endpoints included pharmacokinetics and preliminary clinical activity. Exploratory endpoints including multiplex spatial profiling on tumor specimens to define correlates of response.
Intravesical 2141-V11 was well tolerated, and the MTD was not reached. The RP2D was established at 70 mg. Preliminary clinical activity was observed in 40% of patients, with a median response duration of 20 months. Clinical response was associated with distinct organization of tertiary lymphoid structures, characterized by the presence of DC-CXCL13+ CD4+ and CD8+ T cell triads. Following treatment, responders exhibited decreased proximity between DCs and regulatory T cells (Tregs), whereas non-responders exhibited increased DC-Treg proximity.
Intravesical 2141-V11 demonstrated a favorable safety profile and preliminary antitumor activity. Spatial profiling revealed immune-cell organizations associated with clinical response, identifying candidate biomarkers and potential strategies for therapeutic combinations. These findings support further clinical evaluation of intravesical 2141-V11 in phase II studies.

PMID:
43043010
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement